Examples of 'pegaptanib' in a sentence
Meaning of "pegaptanib"
pegaptanib (adjective) - Refers to a specific type of medication or treatment. Pegaptanib is a drug used to treat a certain eye condition
Show more definitions
- An antiangiogenic used to treat wet age-related macular degeneration.
How to use "pegaptanib" in a sentence
Basic
Advanced
pegaptanib
Pegaptanib has not been studied in pregnant women.
There are no studies on the carcinogenic potential of pegaptanib.
Pegaptanib is optionally provided in the form of a pharmaceutically acceptable salt.
Macugen contains the active ingredient pegaptanib sodium.
Pegaptanib pharmacokinetics have not been studied in patients with hepatic impairment.
The active substance is pegaptanib sodium.
Pegaptanib has to be administered to the designated patient by an ophthalmologist in a sterile environment.
The microspheres were analyzed to determine if pegaptanib was degraded during their preparation.
Pegaptanib is administered by injection into the affected eye by a trained practioner.
Macugen is a solution for injection into the eye that contains the active substance pegaptanib.
The systemic exposure to pegaptanib is expected to be very low after ocular administration.
Overall the pharmacology and toxicology studies support the use of pegaptanib in humans with AMD.
Elimination The excretion of pegaptanib and its breakdown products were not evaluated in humans.
EPAR summary for the public pegaptanib.
Pegaptanib injected into the eye blocks VEGF.
See also
The microsphere preparations were characterized for Pegaptanib content and purity by HPLC.
Pegaptanib is metabolised by endo - and exonucleases.
DNA Incorporation Test results showed that pegaptanib was metabolized in vivo to its nucleoside components.
According to a particular embodiment, the aptamer comprises pegaptanib.
Outside the US pegaptanib is marketed by Pfizer.
In some embodiments, the patient is refractory to one dose of pegaptanib therapy.
In one embodiment, pegaptanib is provided as pegaptanib sodium.
Immediate ( on the day of injection ) and delayed intravitreous haemorrhages may occur following pegaptanib injections.
In another embodiment, pegaptanib microparticles are suspended in a solution comprising pegaptanib.
In yet another embodiment, the VEGF antagonist is an aptamer, such as pegaptanib.
If you are hypersensitive ( allergic ) to pegaptanib sodium or any of the other ingredients.
Pegaptanib does not accumulate in the plasma when administered intravitreally every 6 weeks.
Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
In rabbits, pegaptanib is eliminated as parent drug and metabolites primarily in the urine.
Summary and Conclusion The non-clinical pharmacology and toxicology program for pegaptanib sodium was extensive.
Pegaptanib is marketed as a pre-filled syringe ; however the syringe contains more than the recommended dose.
In other embodiments, the VEGF antagonist is a VEGF aptamer, such as pegaptanib.
Pegaptanib and its salts is a selective vascular endothelial growth factor ( VEGF ) antagonist.
A batch size of 200 milligrams dry microspheres containing pegaptanib was prepared according to the following procedure,.
Pegaptanib is administered in a 0.3 mg dose once every six weeks by intravitreal injection.
Macugen 0.3 mg solution for injection pegaptanib sodium Intravitreal use.
Pegaptanib sodium has not been adequately studied in patients with creatinine clearance below 20 ml / min.
Trough samples had non-measurable pegaptanib plasma concentrations LOQ of 8 ng / mL ; samples taken approx.
Pegaptanib is metabolised by nucleases and therefore cytochrome P450 mediated drug interactions are unlikely.
Macugen 0.3 mg solution for injection pegaptanib sodium.
Immunogenicity Pegaptanib was non-antigenic in animals.
These include ranibizumab, bevacizumab, aflibercept, and, to a lesser extent, pegaptanib.
In one embodiment, the microparticles release pegaptanib over a period of at least about 1-12 months.
Examples of aptamers include, but are not limited to, pegaptanib ( Macugen ® ).
Only ranibizumab and pegaptanib are approved by the FDA for AMD as of April 2007.
